Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program (LC-FAOD DMP)
Latest Information Update: 29 Nov 2024
Price :
$35 *
At a glance
- Drugs Triheptanoin (Primary)
- Indications Lipid metabolism disorders
- Focus Adverse reactions
- Acronyms LC-FAOD DMP
- Sponsors Ultragenyx Pharmaceutical
- 20 Aug 2024 Number of treatment arms are decreased from 5 to 3 by the removal of Triheptanoin Naive Transitioned to Triheptanoin arm and Pregnant unaffected LC-FAOD carrier females arm, thus keeping only 3 cohorts in the study.
- 20 Aug 2024 Planned number of patients changed from 200 to 150.
- 15 Jun 2023 Number of treatment cohorts have been increased from 4 to 5 by the addition of Pregnant unaffected LC-FAOD carrier females' cohort- where no intervention is given. Planned patient enrollment has been decreased.